Global Artificial Pancreas Device Systems Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

13/feb/2018 07:18:34 sai krishna Contatta l'autore

Questo comunicato è stato pubblicato più di 6 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Artificial pancreas device systems are medical devices which links glucose to an insulin infusion pump, monitor reading. These devices are meant to improve glycaemic control in patients with insulin dependent diabetes and in control of nocturnal hypoglycaemia. Pancreas will secrete insulin and glucagon. Type-I diabetes occurs when pancreas produces little or none of insulin needed to regulate blood glucose. Type-II diabetes occurs when pancreas does not produce enough insulin or the body becomes resistant to insulin that is present.



Burgeoning incidence of diabetes is major factor, which is expected to trigger the artificial pancreas devices market. As per WHO, global diabetes cases were increased from 108 Mn to 422Mn from 1980 to 2014. As per, Juvenile Diabetes Research Foundation in 2015, around 1.5Mn cases of type-I were found. Furthermore, growing geriatric population, increase in incidence of lifestyle disorders and obesity which further leads diabetes which in turns propel the growth of artificial pancreas devices market. However, the insulin used in artificial pancreas devices takes long duration to get absorb, lack of awareness, dearth of skilled professionals are the factors which are restraining the growth of artificial pancreas devices systems market.


A sample of this report is available upon request @




Artificial Pancreas Device Systems Market is segmented on basis of technology, application, end user, and geographical regions.


Based on the technology, the global artificial pancreas device systems market is segmented



o    Threshold Suspended Device Systems

o    Treat to Range/Control to Range (TTR/CTR)

o    Treat to Target/ Control to Target (TTR/CTT)



Based on the end user, the global artificial pancreas device systems market is segmented



o    Hospitals

o    Diagnostic centres

o    Ambulatory surgical centres


Based on the application, the global artificial pancreas device systems market is segmented



o    Type 1 Diabetic Patients

o    Type 2 Diabetic Patients


To view TOC of this report is available upon request @




Favourable regulations, increased collaborations coupled with rising prevalence of diabetes are expected to boost the market. FDA is collaborating with government and private research institutions to enhance the clinical studies and to speed up the development of innovative technologies in artificial pancreas device systems. In 2012 October, FDA has released a document of requirements needed for the clinical studies and premarket approval applications for production of artificial pancreas device systems. Juvenile diabetes research foundation (JDRF) funds for the type 1 DM research in order to commercialize first artificial pancreas in 2017. Technological innovations and product developments are propelling the market growth such as Tandem diabetes care outlines its plans in APDS market by initiating R&D phase of its artificial pancreas system. Bigfoot Biomedical’s goal is to create a pump sensor union therapy which could be much simpler than the current counterparts. Beta bionics developed iLet Bionic Pancreas System which delivers both insulin and glucagon in type-1DM patients. Hence, all these products from the major players will be available soon which could increase growth of the market.


Need more information about this report @





Artificial Pancreas Device Systems Market is segmented into North America, Asia-Pacific, Europe, and the Middle East & Africa, Latin America. North America is expected to be as a leader in artificial pancreas device systems market owing to high disposable income, growing prevalence of type 1DM, high adaptation of technological advancements and favourable reimbursement policies. As per, Centre for diseases control and prevention (CDC), type 1 DM accounts for around 5% of total diagnosed adults with diabetes cases in U.S. Europe artificial pancreas device system market is witnessed significant growth due to faster regulatory approvals and robust clinical trial pipeline. For example, AP@Home is a project initiated by European Union and completed in 2015, which was focussed on development of combined device capable of administering insulin and monitoring glucose levels of the patient with the help of single catheter. Asia Pacific artificial pancreas devices market is anticipated to offer lucrative opportunities due to high prevalence and incidence of diabetes, large population pool, and change in lifestyle of the people etc.


Some of the companies in artificial pancreas device systems market are MEDTRUM TECHNOLOGIES (UK), Medtronic (U.S), Tandem Diabetes Care, Inc. (U.S), Beta Bionics (U.S), Johnson & Johnson (U.S), Insulet Corporation (U.S) and Bigfoot Biomedical, INC.(U.S).


Get access to full summary @


About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.


Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX


Toll Free (US): +1-866-598-1553

Website @

blog comments powered by Disqus è un servizio offerto da Factotum Srl